Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer: An Open-label, Single-armed Phase II Trial

NCT02815007 is registered in ClinicalTrials.gov with Yuankai Shi as lead sponsor.

NCT NCT02815007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02815007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer: An Open-label, Single-armed Phase II Trial
Lead sponsor
Yuankai Shi
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2016
Completion date
June 30, 2018
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced egfr-tki-resistant non-small cell lung cancer